Program
LY3938577
A development code.
In Eli Lilly's pipeline, insulin receptor agonist
. Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Eli Lilly.
Furthest: phase 2, since Oct 9, 20253 company-led studies, 1 open or runningNext primary completion: Nov 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 31 open or running | phase 2since Oct 9, 2025 | Nov 10, 2023 | Nov 2026phase 2 · NCT07215312 |
- Named in Eli Lilly’s own pipeline as
GS Insulin Receptor Agonist
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 10, 2023First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT06132126 · 66 enrolled · United States
- Feb 20, 2024Phase 1 study in Diabetes Mellitus, Type 1NCT06280703 · 121 enrolled · Germany
- Oct 9, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT07215312 · 100 enrolled · United States, Argentina
Ahead
- Nov 2026Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07215312
TargetBeta
“insulin receptor agonist”the company's pipeline, read by Claude · source
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07215312Diabetes Mellitus, Type 2 · United States, Argentina | 2 | Active, not recruiting | Nov 2026 | 100 |
| NCT06280703Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Oct 3, 2026 | 121 |
| NCT06132126Diabetes Mellitus, Type 2 · United States | 1 | Completed | Jun 28, 2024 | 66 |
How it is read
Names in the registry
- “LY3938577”, 4 entries
Codes read as this program: LY3938577.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 2 studies
- Diabetes Mellitus, Type 1, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.